Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by M101on Jul 15, 2021 1:35pm
113 Views
Post# 33552949

RE:Is PMN worth the Investment?

RE:Is PMN worth the Investment?YES imho, and a year ago I would have said no.

It is wise, because the market has not yet digested the valuation just awarded a minor competitor with a 2nd-hand drug, and while the market is also rightly skeptical of PMN management, those concerns have been alleviated somewhat with the CEO's departure.  PMN is still valued as if bankruptcy is a near term risk, but that is no longer true.
In short the risk/reward has changed significantly for the better over the last 6 months (like 10X better not 2X) while the market has remained in an emotional funk because the market is not rational, it's a player not an investor. 




.  
<< Previous
Bullboard Posts
Next >>